BTI615
/ Chengdu Brilliant Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 23, 2025
Efficacy of BTI615 on malignant cells expansion and bone marrow fibrosis in a myelofibrosis mice model.
(ASCO 2025)
- "Here we verified that BTI615, a synthetic active TGF-β modulating peptide, rescued malignant cells expansion and bone marrow fibrosis to restore hematopoiesis in a romiplostim-induced MF model. Given its effective suppression on hyperplasia of atypical megakaryocytes, inflammation, marrow fibrosis and the ultimate recovery of hematopoietic function via modulating TGF-β signaling, BTI615 has a great potential to be the next generation therapeutic approach for MF."
Preclinical • Fibrosis • Immunology • Myelofibrosis • TGFB1
1 to 1
Of
1
Go to page
1